Literature DB >> 6589229

The human c-abl oncogene in the Philadelphia translocation.

J Groffen, J R Stephenson, N Heisterkamp, C Bartram, A de Klein, G Grosveld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6589229     DOI： 10.1002/jcp.1041210421

Source DB:  PubMed          Journal:  J Cell Physiol Suppl        ISSN： 0737-1462


× No keyword cloud information.
  7 in total

1.  Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.

Authors:  Andrew S Dixon; Geoffrey D Miller; Benjamin J Bruno; Jonathan E Constance; David W Woessner; Trevor P Fidler; James C Robertson; Thomas E Cheatham; Carol S Lim
Journal:  Mol Pharm       Date:  2011-12-12       Impact factor: 4.939

Review 2.  Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:  Hyewon Lee; Igor Novitzky Basso; Dennis Dong Hwan Kim
Journal:  Int J Hematol       Date:  2021-03-27       Impact factor: 2.490

3.  Confirmation and refinement of the localisation of the c-MEL locus on chromosome 19 by physical and genetic mapping.

Authors:  E Nimmo; R A Padua; D Hughes; J D Brook; R Williamson; K J Johnson
Journal:  Hum Genet       Date:  1989-03       Impact factor: 4.132

4.  Improving the solubility and antileukemia activity of Wnt/β-catenin signaling inhibitors by disrupting molecular planarity.

Authors:  Yong Ai; Srilatha Sakamuru; Greg Imler; Menghang Xia; Fengtian Xue
Journal:  Bioorg Med Chem       Date:  2022-06-20       Impact factor: 3.461

5.  All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

Authors:  Ophélie Cassuto; Maeva Dufies; Arnaud Jacquel; Guillaume Robert; Clémence Ginet; Alix Dubois; Amine Hamouda; Alexandre Puissant; Fredéric Luciano; Jean-Michel Karsenti; Laurence Legros; Jill Patrice Cassuto; Pascal Lenain; Patrick Auberger
Journal:  Oncotarget       Date:  2012-12

Review 6.  Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.

Authors:  Simona Soverini; Manuela Mancini; Luana Bavaro; Michele Cavo; Giovanni Martinelli
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

Review 7.  Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.

Authors:  Sara De Santis; Cecilia Monaldi; Manuela Mancini; Samantha Bruno; Michele Cavo; Simona Soverini
Journal:  Onco Targets Ther       Date:  2022-01-25       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.